絞り込み

16645

広告

新型肺炎 空港や港の検疫所でもウイルス検査実施へ 厚労省

中国で新型コロナウイルスによる肺炎が拡大する中、厚生労働省は感染者をより早期に発見するため、空港や港にある検疫所でもウイルス検査を実施していくことになりました。...

  1. 「クイーン」のブライアン・メイさん 京都...
  2. 新型肺炎「指定感染症」に きょう閣議決定...
  3. ルマテペロンは統合失調症の症状を軽減 (...
  4. 「嘔吐後の肺炎=誤嚥性肺炎」ではない! ...

ニュース一覧

EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.

著者 Chu MQ , Zhang TJ , Xu ZJ , Gu Y , Ma JC , Zhang W , Wen XM , Lin J , Qian J , Zhou JD
J Cell Mol Med.2019 Dec 03 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Accumulating studies have proved EZH2 dysregulation mediated by mutation and expression in diverse human cancers including AML. However, the expression pattern of EZH2 remains controversial in acute myeloid leukaemia (AML). EZH1/2 expression and mutation were analysed in 200 patients with AML. EZH2 expression was significantly decreased in AML patients compared with normal controls but not for EZH1 expression. EZH2 mutation was identified three of the 200 AML patients (1.5%, 3/200), whereas none of the patients harboured EZH1 mutation (0%, 0/200). EZH2 expression and mutation were significantly associated with -7/del(7) karyotypes. Moreover, lower EZH2 expression was associated with older age, higher white blood cells, NPM1 mutation, CEBPA wild-type and WT1 wild-type. Patients with EZH2 mutation showed shorter overall survival (OS) and leukaemia-free survival (LFS) than patients without EHZ2 mutation after receiving autologous or allogeneic haematopoietic stem cell transplantation (HSCT). However, EZH2 expression has no effect on OS and LFS of AML patients. Notably, in EZH2 low group, patients undergone HSCT had significantly better OS and LFS compared with patients only received chemotherapy, whereas no significant difference was found in OS and LFS between chemotherapy and HSCT patients in EZH2 high group. Collectively, EZH2 dysregulation caused by mutation and under-expression identifies specific subtypes of AML EZH2 dysregulation may be acted as potential biomarkers predicting prognosis and guiding the treatment choice between transplantation and chemotherapy.
PMID: 31794134 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード